WO2005101013A3 - Materials and methods for screening modulators of neural regneration - Google Patents

Materials and methods for screening modulators of neural regneration Download PDF

Info

Publication number
WO2005101013A3
WO2005101013A3 PCT/EP2005/003946 EP2005003946W WO2005101013A3 WO 2005101013 A3 WO2005101013 A3 WO 2005101013A3 EP 2005003946 W EP2005003946 W EP 2005003946W WO 2005101013 A3 WO2005101013 A3 WO 2005101013A3
Authority
WO
WIPO (PCT)
Prior art keywords
materials
regneration
neural
methods
screening modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/003946
Other languages
French (fr)
Other versions
WO2005101013A2 (en
Inventor
Milos Pekny
Marcela Pekna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REGLIA AB
Original Assignee
REGLIA AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REGLIA AB filed Critical REGLIA AB
Priority to EP05739891A priority Critical patent/EP1782072A2/en
Publication of WO2005101013A2 publication Critical patent/WO2005101013A2/en
Publication of WO2005101013A3 publication Critical patent/WO2005101013A3/en
Priority to US11/581,207 priority patent/US20070054325A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides materials and methods used to identify modulators of neurogenesis and neuroregeneration, and use of said modulators in the treatment of neurodegenerative diseases and neurological injury.
PCT/EP2005/003946 2004-04-15 2005-04-14 Materials and methods for screening modulators of neural regneration Ceased WO2005101013A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05739891A EP1782072A2 (en) 2004-04-15 2005-04-14 Materials and methods for screening modulators of neural regneration
US11/581,207 US20070054325A1 (en) 2005-04-14 2006-10-13 Materials and methods for screening modulators of neural regeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56286604P 2004-04-15 2004-04-15
US60/562,866 2004-04-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/581,207 Continuation-In-Part US20070054325A1 (en) 2005-04-14 2006-10-13 Materials and methods for screening modulators of neural regeneration

Publications (2)

Publication Number Publication Date
WO2005101013A2 WO2005101013A2 (en) 2005-10-27
WO2005101013A3 true WO2005101013A3 (en) 2006-03-02

Family

ID=34975236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003946 Ceased WO2005101013A2 (en) 2004-04-15 2005-04-14 Materials and methods for screening modulators of neural regneration

Country Status (2)

Country Link
EP (1) EP1782072A2 (en)
WO (1) WO2005101013A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891438A4 (en) * 2005-05-27 2008-12-10 Advanced Cell Tech Inc METHODS FOR IDENTIFYING LIGANDS FOR STEM CELLS AND CELLS DERIVED THEREFROM
WO2009083185A2 (en) * 2007-12-28 2009-07-09 Fovea Pharmaceuticals Sa Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders
US20140329761A1 (en) * 2011-06-20 2014-11-06 The University Of Queensland Prevention and treatment of acute inflammatory conditions
GB201619637D0 (en) 2016-11-21 2017-01-04 Pekna Marcela And Pekny Milos And Stokowska Anna C3a receptor agonists

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
EP0814158A2 (en) * 1996-06-17 1997-12-29 Smithkline Beecham Corporation Human C3a receptor variant; uses in diagnostics and therapeutics
WO1999015490A1 (en) * 1997-09-23 1999-04-01 Smithkline Beecham Corporation C3a receptor ligands
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001000198A2 (en) * 1999-06-29 2001-01-04 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity
US20010036650A1 (en) * 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
US6358720B1 (en) * 1997-04-28 2002-03-19 Helix Research Institute Serine/theonine protein kinase
WO2002038767A2 (en) * 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002044737A2 (en) * 2000-11-29 2002-06-06 Lifespan Biosciences, Inc. Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
WO2002079478A2 (en) * 2001-03-30 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
WO2002102768A2 (en) * 2001-06-18 2002-12-27 The Rockefeller University Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
US20030022310A1 (en) * 1995-02-17 2003-01-30 Human Genome Sciences, Inc. Human G-protein coupled receptor
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US20010036650A1 (en) * 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
US20030022310A1 (en) * 1995-02-17 2003-01-30 Human Genome Sciences, Inc. Human G-protein coupled receptor
EP0814158A2 (en) * 1996-06-17 1997-12-29 Smithkline Beecham Corporation Human C3a receptor variant; uses in diagnostics and therapeutics
US6358720B1 (en) * 1997-04-28 2002-03-19 Helix Research Institute Serine/theonine protein kinase
WO1999015490A1 (en) * 1997-09-23 1999-04-01 Smithkline Beecham Corporation C3a receptor ligands
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001000198A2 (en) * 1999-06-29 2001-01-04 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity
WO2002038767A2 (en) * 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002044737A2 (en) * 2000-11-29 2002-06-06 Lifespan Biosciences, Inc. Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
WO2002079478A2 (en) * 2001-03-30 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
WO2002102768A2 (en) * 2001-06-18 2002-12-27 The Rockefeller University Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BABAJKO SYLVIE ET AL: "Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SH neuroblastoma cells", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 134, no. 4, 1996, pages 474 - 480, XP008056999, ISSN: 0804-4643 *
EMBER J A ET AL: "DESIGNING SYNTHETIC SUPERAGONISTS OF C3A ANAPHYLATOXIN", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 30, no. 15, 16 April 1991 (1991-04-16), pages 3603 - 3612, XP000147256, ISSN: 0006-2960 *
KOHZUKI M ET AL: "ENDOTHELIN RECEPTORS IN ISCHEMIC RAT BRAIN AND ALZHEIMER BRAIN", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, US, vol. 26, no. SUPPL 3, 1995, pages S329 - S331, XP009023544, ISSN: 0160-2446 *
KRETZSCHMAR T ET AL: "Synthetic peptides as antagonists of the anaphylatoxin C3a", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 210, no. 1, 15 November 1992 (1992-11-15), pages 185 - 191, XP002116090, ISSN: 0014-2956 *
LAURSEN LISBETH S ET AL: "Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: Substrate residues distant from the scissile bond are critical for proteolysis", BIOCHEMICAL JOURNAL, vol. 367, no. 1, 1 October 2002 (2002-10-01), pages 31 - 40, XP008056959, ISSN: 0264-6021 *
LIU XIN-JIN ET AL: "Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 35, 31 August 2001 (2001-08-31), pages 32419 - 32422, XP008056965, ISSN: 0021-9258 *
MUKHERJEE PIALI ET AL: "The role of complement anaphylatoxin C5a in neurodegeneration: Implications in Alzheimer's disease", JOURNAL OF NEUROIMMUNOLOGY, vol. 105, no. 2, 26 June 2000 (2000-06-26), pages 124 - 130, XP008057090, ISSN: 0165-5728 *
O'BARR S A ET AL: "Neuronal expression of a functional receptor for the C5a complement activation fragment.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 2001, vol. 166, no. 6, 15 March 2001 (2001-03-15), pages 4154 - 4162, XP008057085, ISSN: 0022-1767 *
OKAZAKI NORIKO ET AL: "Interaction of the Unc-51-like kinase and microtubule-associated protein light chain 3 related proteins in the brain: Possible role of vesicular transport in axonal elongation", MOLECULAR BRAIN RESEARCH, vol. 85, no. 1-2, 28 December 2000 (2000-12-28), pages 1 - 12, XP008056971, ISSN: 0169-328X *
RAJAH ROOPMATHY ET AL: "7S nerve growth factor is an insulin-like growth factor-binding protein protease", ENDOCRINOLOGY, vol. 137, no. 7, 1996, pages 2676 - 2682, XP008056980, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2005101013A2 (en) 2005-10-27
EP1782072A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
CL2007003155A1 (en) COMPOUNDS DERIVED FROM 3,7-DIAZABICICLO [3.3.0] OCTANO OR 3,7-DIAZABICICLO [3.3.1] NONANO, NEURONAL NICOTINIC RECEIVER MODULATORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CNS DISORDERS.
MY145305A (en) Cyclopropyl amines as modulators of the histamine h3 receptor
WO2007138485A3 (en) Ppar modulators
WO2004071382A3 (en) Substituted heterocycles
WO2008029169A3 (en) Method of treating respiratory disorders
WO2007134350A3 (en) Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2006013087A8 (en) Human monoclonal antibodies against human il-4
WO2006138714A3 (en) Naphthyridine compounds
WO2007035092A3 (en) Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005101013A3 (en) Materials and methods for screening modulators of neural regneration
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2007002188A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2006009950A3 (en) Aldos as modifiers of the igf pathway and methods of use
WO2005023253A8 (en) Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
WO2006099185A3 (en) Brsk1s as modifiers of the pten/akt pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11581207

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005739891

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11581207

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005739891

Country of ref document: EP